|
Complimentary CME Publication Explores Targeted Therapies for Advanced Differentiated Thyroid Carcinoma
|
|
BALTIMORE, MD—October 28, 2014—Although differentiated thyroid cancer is highly treatable, response to conventional therapies among patients with locally advanced or metastatic DTC is poor. New targeted therapies have shown encouraging results although there are often associated toxicities to consider. To help clinicians balance the safety and efficacy of novel therapeutic agents when treating patients with advanced DTC, Med-IQ, an award-winning, ACCME-accredited provider of continuing medical education (CME), has released a complimentary, CME-certified publication that explores contemporary pharmacotherapy for this condition.
Exploring New Options for Advanced Differentiated Thyroid Carcinoma provides endocrinologists, oncologists, and oncology nurses with information about new targeted agents in development and strategies for managing treatment-related toxicities for their patients with advanced DTC. Leading experts provide their perspectives on the promise of these agents and the practicality of balancing efficacy and treatment-related toxicities.
“Although DTC is usually curable, a subgroup of patients fail initial treatment with surgery and radioactive iodine (RAI). In patients with RAI refractory progressive DTC, new treatment options are making a difference for these patients," said Marcia S. Brose, MD, PhD, Associate Professor at the Abramson Cancer Center in Philadelphia, PA. "As the global incidence and mortality rate of thyroid cancer continues to increase, it is important for us to continue to explore novel agents and develop strategies for improving treatment responses and manage side effects.”
|
|
|
| FACULTY |
|
Marcia S. Brose, MD, PhD
Associate Professor
Department of Otorhinolaryngology: Head & Neck Surgery
Department of Medicine, Division of Hematology/Oncology
Abramson Cancer Center
Philadelphia, PA
|
|
|
R. Michael Tuttle, MD
Professor of Medicine
Memorial Sloan-Kettering Cancer Center
New York, NY
|
|
|
|
|
For complimentary access to this educational opportunity, visit www.Med-IQ.com/a756. For more information, please call (toll-free) 866 858 7434 or e-mail info@med-iq.com.
This activity is approved for AMA PRA Category 1 Credit™ and is supported by an educational grant from Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals.
|
|
|
About Med-IQ
Med-IQ, America's most respected provider of continuing medical education (CME), inspires healthcare professionals through award-winning activities that deliver sophisticated outcomes-based educational designs with measurable results in professional competence and performance. Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the California Board of Registered Nursing (CBRN), and the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing medical education to physicians, nurses, and pharmacists, respectively.
Med-IQ, a leader in the development of performance improvement (PI) and quality improvement (QI) CME initiatives, has been recognized by the Alliance for Continuing Education in the Health Professions for our excellence in CE research (William Campbell Felch Award 2013, 2011), educational collaborations (2013), outstanding CME outcomes assessment (2012), and exceptional leadership (Leadership Award 2013, President’s Award 2012). To learn more about Med-IQ, visit www.Med-IQ.com, like us on Facebook, follow us on Twitter, and connect with us on LinkedIn.
For more information, contact:
Amy Caswell
Senior Audience Development Manager
866 858 7434
info@med-iq.com
Med-IQ.
Inspiring Medical Education.
|
|
|
|
|
close
